International Slow Grain Day: From "incurable disease" to curable "chronic disease"

International Slow Grain Day: From "incurable disease" to curable "chronic disease", breakthrough progress in targeted therapy for chronic particles

International CML Day: From "incurable disease" to curable "chronic disease" CML targeted therapy welcomes breakthrough progress International CMV Day: from "incurable disease" to curable "chronic disease" CML targeted therapy welcomes Breakthrough progress

China News Service, Beijing, September 22 (Reporter Yu Zhanyi) September 22 is the International Slow Particle Day.
On this occasion, Professor Jiang Qian, deputy director of the Department of Hematology, Peking University People’s Hospital, said that with the continuous development of modern medicine , Chronic granule has changed from an "incurable disease" to a treatable and controllable "chronic disease".
At present, innovative drugs have been submitted for new drug marketing applications in China
.

Chronic myelogenous leukemia (hereinafter referred to as "chronic myeloid") was once considered an "incurable disease", and was the first human tumor to be shown to be related to chromosomal abnormalities, due to the interaction between chromosomes 9 and 22 in the patient's body.
Translocation, resulting in the formation of a new gene
.

CML is a malignant tumor formed by clonal proliferation of bone marrow hematopoietic stem cells, which accounts for 15% of adult leukemias

It is understood that in 2001, the world's first tyrosine kinase inhibitor (TKI) appeared, marking that tumor therapy has entered the era of targeted therapy
.

Over the past 20 years, the treatment pattern of slow particles has also undergone earth-shaking changes

"With the continuous development of modern medicine, CML has changed from an'incurable disease' to a curable and controllable'chronic disease.
' Drug difficulties
.

" Jiang Qian pointed out that before the emergence of TKI, chemotherapy, interferon therapy and bone marrow transplantation were traditional treatments for chronic particles, but the therapeutic effect was not satisfactory

Acquired drug resistance has always been a major challenge in CML therapy
.

As the main therapeutic drug at present, some patients can obtain ideal curative effect after receiving TKI treatment

According to reports, there is currently no third-generation TKI drugs in China.
For patients with drug resistance, poor efficacy, or advanced chronic particles, the third-generation TKI is "just needed
.

" Especially for the needs of patients with T315I mutation, corresponding clinical research projects have been carried out at home and abroad in recent years

"The third-generation innovative TKI drugs in China are designed for the T315I mutation.
I very much look forward to such original and innovative drugs that can provide more treatment opportunities for patients with drug-resistant chronic particles, especially patients with multi-drug resistance, and extend their lives.

"Jiang Qian said that at present, innovative drugs have been submitted for new drug marketing applications in China, and they have been included in priority review and breakthrough treatment varieties
.

It is believed that with the introduction of new drugs and the standardization of kinase mutation detection, the existing drug resistance problem is expected to be overcome, allowing more patients to benefit from it

With the widespread application of TKI, the survival period of chronic granule patients has been close to that of normal people of the same age, and more and more studies have begun to pay attention to the quality of life of patients
.

Jiang Qian said that although the disease has been well controlled, many young patients still hide their condition, worrying that once they are made public, they may be viewed from another perspective, which will cause great resistance to their future studies and job hunting

"The ability of CML patients to return to society is very powerful, and their contribution to society is also very large
.

There are many excellent CML patients who have made good contributions to their work.
These people should be regarded as normal people.